Prevosto Claudia, Zancolli Marta, Canevali Paolo, Zocchi Maria Raffaella, Poggi Alessandro
Laboratory of Experimental Oncology D, National Cancer Research Institute, 16132-Genoa, Italy.
Haematologica. 2007 Jul;92(7):881-8. doi: 10.3324/haematol.11240.
Mesenchymal stem cells (MSC) have been proposed as a way to treat graft-versus-host disease based of their immunosuppressive effect. We analyzed whether regulatory T cells can be generated in co-cultures of peripheral blood mononuclear cells (PBMC) and MSC.
MSC were obtained from the bone marrow of four healthy donors and nine patients with acute leukemia in complete remission following chemotherapy. Short-term (4 days) co-cultures of MSC and autologous or allogeneic PBMC were set up, the lymphocytes harvested and their regulatory activity assessed.
Lymphocytes harvested from MSC-PBMC co-cultures strongly inhibit (up to 95%) mixed lymphocyte reaction (MLR), recall to alloantigen, and CD3- or PHA-induced lymphocyte proliferation. These lymphocytes, termed regulatory cells (Regc), were all CD45+CD2+ with variable proportions of CD25+ cells (range 40-75% n=10) and a minor fraction expressed CTLA4 (2-4%, n=10) or glucocorticoid-induced tumor necrosis factcor receptor-related gene (0.5-4% n=10). Both CD4+ and CD8+ Regc purified from MSC-PBMC co-cultures strongly inhibited lymphocyte proliferation at a 1:100 Regc:responder cell ratio. CD4+ Regc expressed high levels of forkhead box P3 (Foxp3) mRNA while CD8+ Regc did not. The effectiveness of Regc, whether CD4+ or CD8+, was 100-fold higher than that of CD4+CD25+high regulatory T cells. Regc were also generated from highly purified CD25- PBMC or CD4+ or CD8+ T cell subsets. Soluble factors, such as interleukin-10, transforming growth factor-b and prostaglandin E2 did not appear to be involved in the generation of Regc or in the Regc-mediated immunosuppressive effect. Furthermore, cyclosporin A did not affect Regc generation or the immunosuppression induced by Regc.
These findings indicate that powerful regulatory CD4+ or CD8+ lymphocytes are generated in co-cultures of PBMC with MSC. This strongly suggests that these regulatory cells may amplify the reported MSC-mediated immunosuppressive effect.
间充质干细胞(MSC)因其免疫抑制作用被认为是治疗移植物抗宿主病的一种方法。我们分析了在外周血单个核细胞(PBMC)与MSC共培养体系中是否能产生调节性T细胞。
从4名健康供者及9名化疗后完全缓解的急性白血病患者的骨髓中获取MSC。建立MSC与自体或异体PBMC的短期(4天)共培养体系,收集淋巴细胞并评估其调节活性。
从MSC-PBMC共培养体系中收获的淋巴细胞能强烈抑制(高达95%)混合淋巴细胞反应(MLR)、对同种异体抗原的回忆反应以及CD3或PHA诱导的淋巴细胞增殖。这些淋巴细胞被称为调节细胞(Regc),均为CD45+CD2+,CD25+细胞比例各异(范围40 - 75%,n = 10),一小部分表达CTLA4(2 - 4%,n = 10)或糖皮质激素诱导的肿瘤坏死因子受体相关基因(0.5 - 4%,n = 10)。从MSC-PBMC共培养体系中纯化的CD4+和CD8+ Regc在Regc与反应细胞比例为1:100时均能强烈抑制淋巴细胞增殖。CD4+ Regc表达高水平的叉头框P3(Foxp3)mRNA,而CD8+ Regc不表达。无论CD4+还是CD8+,Regc的效力都比CD4+CD25+高调节性T细胞高100倍。Regc也可从高度纯化的CD25- PBMC或CD4+或CD8+ T细胞亚群中产生。可溶性因子,如白细胞介素-10、转化生长因子-β和前列腺素E2似乎不参与Regc的产生或Regc介导的免疫抑制作用。此外,环孢素A不影响Regc的产生或Regc诱导的免疫抑制作用。
这些发现表明在PBMC与MSC的共培养体系中可产生强大的调节性CD4+或CD8+淋巴细胞。这强烈提示这些调节细胞可能增强已报道的MSC介导的免疫抑制作用。